Arcutis Biotherapeutics, Inc. (ARQT) Cash Flow Statement
Arcutis Biotherapeutics, Inc. (ARQT) generated $39.3M of operating cash flow over the twelve months to 2026-06-30, spent $158000 on capital expenditure and had free cash flow of $39.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -257.7 | -247.1 | -112.2 | -5.6 | 39.3 | |
| Capital expenditure | 0.3 | 0.4 | 0.1 | 0.7 | -0.2 | |
| Free cash flow | -258.0 | -247.5 | -112.3 | -6.3 | 39.2 | |
| Stock-based compensation | 32.7 | 38.8 | 41.7 | 40.4 | — |
USD millions · SEC XBRL
Arcutis Biotherapeutics, Inc. — questions
- What is Arcutis Biotherapeutics, Inc.'s operating cash flow?
- $39.3M over the twelve months to 2026-06-30.
- How much does Arcutis Biotherapeutics, Inc. spend on capital expenditure?
- $158000 over the twelve months to 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s free cash flow?
- $39.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.